Bronson Crouch - Instil Bio Chairman CEO
| TIL Stock | USD 26.40 0.00 0.00% |
Insider
Bronson Crouch is Chairman CEO of Instil Bio
| Age | 51 |
| Address | 3963 Maple Avenue, Dallas, TX, United States, 75219 |
| Phone | 972 499 3350 |
| Web | https://instilbio.com |
Bronson Crouch Latest Insider Activity
Tracking and analyzing the buying and selling activities of Bronson Crouch against Instil Bio stock is an integral part of due diligence when investing in Instil Bio. Bronson Crouch insider activity provides valuable insight into whether Instil Bio is net buyers or sellers over its current business cycle. Note, Instil Bio insiders must abide by specific rules, including filing SEC forms every time they buy or sell Instil Bio'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Bronson Crouch over two months ago Acquisition by Bronson Crouch of 50000 shares of Instil Bio at 66.1 subject to Rule 16b-3 |
Instil Bio Management Efficiency
The company has Return on Asset of (0.1245) % which means that on every $100 spent on assets, it lost $0.1245. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.4865) %, meaning that it generated no profit with money invested by stockholders. Instil Bio's management efficiency ratios could be used to measure how well Instil Bio manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.5. The value of Return On Capital Employed is expected to slide to -0.53. At this time, Instil Bio's Total Assets are quite stable compared to the past year. Net Tangible Assets is expected to rise to about 670.4 M this year, although the value of Other Current Assets will most likely fall to about 8.8 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Christopher Ogden | CytomX Therapeutics | 40 | |
| Lieping MD | NextCure | 67 | |
| James Brady | Spero Therapeutics | N/A | |
| Daniel Welch | Nuvation Bio | 63 | |
| CPA CPA | NextCure | 61 | |
| Susannah Walpole | Spero Therapeutics | N/A | |
| David MD | Nuvation Bio | 54 | |
| W Vernon | Nuvation Bio | 65 | |
| Uri MD | Assembly Biosciences | 52 | |
| Timothy Mayer | NextCure | 59 | |
| Gary Hattersley | Nuvation Bio | 57 | |
| MD FACP | NextCure | 71 | |
| MHROD SHRMSCP | Assembly Biosciences | N/A | |
| Julia Wilson | Achilles Therapeutics PLC | N/A | |
| Stacy Markel | Nuvation Bio | 59 | |
| Solomon Langermann | NextCure | 64 | |
| Robert Bazemore | Nuvation Bio | 53 | |
| Michael MSBA | NextCure | 63 | |
| MBA BS | CytomX Therapeutics | 45 | |
| Jamie Moore | CytomX Therapeutics | N/A | |
| Sergio Quezada | Achilles Therapeutics PLC | 49 | |
Management Performance
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.12 |
Instil Bio Leadership Team
Elected by the shareholders, the Instil Bio's board of directors comprises two types of representatives: Instil Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Instil. The board's role is to monitor Instil Bio's management team and ensure that shareholders' interests are well served. Instil Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Instil Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sandeep MD, CFO Officer | ||
| Timothy Moore, Chief Officer | ||
| Bronson Crouch, Chairman CEO | ||
| Sumita JD, Compliance, Legal | ||
| Mark Dudley, Chief Officer | ||
| Robert MBBS, Head Development |
Instil Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Instil Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.12 | ||||
| Current Valuation | 158.81 M | ||||
| Shares Outstanding | 6.53 M | ||||
| Shares Owned By Insiders | 12.86 % | ||||
| Shares Owned By Institutions | 80.70 % | ||||
| Number Of Shares Shorted | 303.2 K | ||||
| Price To Earning | 18.31 X | ||||
| Price To Book | 1.10 X | ||||
| Price To Sales | 55,330 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Instil Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Instil Stock please use our How to buy in Instil Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Instil Bio. If investors know Instil will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Instil Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.56) | Return On Assets (0.12) | Return On Equity (0.49) |
The market value of Instil Bio is measured differently than its book value, which is the value of Instil that is recorded on the company's balance sheet. Investors also form their own opinion of Instil Bio's value that differs from its market value or its book value, called intrinsic value, which is Instil Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Instil Bio's market value can be influenced by many factors that don't directly affect Instil Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Instil Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Instil Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Instil Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.